← All news

FROM THE NEWS FEED

How Gilgamesh Landed a $1.2B AbbVie Deal in Psychedelics

2026-03-31 β€’ PsyMed Ventures

Article summary

Jonathan Sporn (CEO + Founder of Gilgamesh Pharma) joins for a deep dive into next-gen psychedelic medicines, why duration matters for real-world clinical use, and more.

Continue to the original publication for the complete article.